Yuri Mackeyev
Overview
Explore the profile of Yuri Mackeyev including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
301
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schwartz-Duval A, Mackeyev Y, Mahmud I, Lorenzi P, Gagea M, Krishnan S, et al.
ACS Nano
. 2024 Jan;
18(3):1865-1881.
PMID: 38206058
Nanoparticle delivery to solid tumors is a prime challenge in nanomedicine. Here, we approach this challenge through the lens of biogeochemistry, the field that studies the flow of chemical elements...
2.
Jackson N, Hill I, Alhussan A, Bromma K, Morgan J, Abousaida B, et al.
Cancer Nanotechnol
. 2023 Oct;
14(1):75.
PMID: 37781236
Background: Radiotherapy (RT) is an essential component in the treatment regimens for many cancer patients. However, the dose escalation required to improve curative results is hindered due to the normal...
3.
Seneviratne D, Saifi O, Mackeyev Y, Malouff T, Krishnan S
Cells
. 2023 Jul;
12(10).
PMID: 37408232
BNCT is a high-linear-energy transfer therapy that facilitates tumor-directed radiation delivery while largely sparing adjacent normal tissues through the biological targeting of boron compounds to tumor cells. Tumor-specific accumulation of...
4.
Goel M, Mackeyev Y, Krishnan S
Cancer Nanotechnol
. 2023 Mar;
14(1):15.
PMID: 36865684
In the last three decades, radiopharmaceuticals have proven their effectiveness for cancer diagnosis and therapy. In parallel, the advances in nanotechnology have fueled a plethora of applications in biology and...
5.
Raghuram S, Mackeyev Y, Symons J, Zahra Y, Gonzalez V, Mahadevan K, et al.
Biomaterials
. 2022 Nov;
291:121887.
PMID: 36368139
Major impediments to conveyance of intravenously administered drugs to tumors are biofouling, opsonization, and rapid clearance from the circulation by macrophages and reticuloendothelial phagocytes. Cloaking nanoparticles with stealth epilayers partly...
6.
Ranjan Rauta P, Mackeyev Y, Sanders K, Kim J, Gonzalez V, Zahra Y, et al.
Sci Adv
. 2022 Nov;
8(45):eabm9729.
PMID: 36367938
Coating nanoparticles with stealth epilayers increases circulation time by evading opsonization, macrophage phagocytosis, and reticuloendothelial sequestration. However, this also reduces internalization by cancer cells upon reaching the tumor. We designed...
7.
Gupta K, Jones J, de Araujo Farias V, Mackeyev Y, Singh P, Quinones-Hinojosa A, et al.
Front Oncol
. 2022 Jun;
12:840241.
PMID: 35664781
Treatment resistance is observed in all advanced cancers. Colorectal cancer (CRC) presenting as colorectal adenocarcinoma (COAD) is the second leading cause of cancer deaths worldwide. Multimodality treatment includes surgery, chemotherapy,...
8.
Shukla S, Fletcher S, Chauhan J, Chalfant V, Riveros C, Mackeyev Y, et al.
Cancer Gene Ther
. 2022 Apr;
29(11):1550-1557.
PMID: 35440696
The proto-oncogene cellular myelocytomatosis (c-Myc) is a transcription factor that is upregulated in several human cancers. Therapeutic targeting of c-Myc remains a challenge because of a disordered protein tertiary structure....
9.
Bhattarai S, Mackeyev Y, Venkatesulu B, Krishnan S, Singh P
Nanoscale
. 2021 Nov;
13(45):19056-19065.
PMID: 34757363
CXC chemokine receptor 4 (CXCR4) is overexpressed on most breast cancer cell surfaces including triple negative breast cancer (TNBC) which lacks traditional receptor overexpression. We targeted gold nanoparticles (GNPs) to...
10.
Wang J, Salzillo T, Jiang Y, Mackeyev Y, Fuller C, Chung C, et al.
Radiother Oncol
. 2021 Jun;
161:55-64.
PMID: 34089753
Background: Gadolinium-based contrast is often used when acquiring MR images for radiation therapy planning for better target delineation. In some situations, patients may still have residual MRI contrast agents in...